We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cancer Research UK and Stitch Strengthen Their Partnership, Collaborating on Two New Studies

A scientist holding a rack of samples.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Cancer Research UK and Stitch are pleased to announce the expansion of their partnership, focused on enhancing the patient experience within clinical trials.

In their work together to date, Cancer Research UK and Stitch have worked tirelessly to empower patients in managing their trial journey and capturing invaluable feedback.


After a successful pilot study launched in January 2023 across two research sites in the Experimental Cancer Medicine Centres network, the charity’s Centre for Drug Development has decided to further integrate the Stitch platform into their clinical trial initiatives. The initial pilot demonstrates impressive participant engagement and survey response rates, providing Cancer Research UK with crucial insights to enhance the design of their trials.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Director of Drug Development at Cancer Research UK, Dr Stephen Nabarro, commented on the pilot’s success, stating:


“The Stitch platform used in our Cancer Research UK trials was designed with patients, for patients. As we continue to track the key measures of success during the pilot study, it is rewarding to see the increased level of support we have been able to provide to trial participants, and the feedback provided from participants has been invaluable.


We are excited about expanding our use of the Stitch platform to two additional trials and to explore the potential benefit of new features such as giving caregivers access to Stitch, and also using the application to provide participants with updates on progress of the trial.”


This positive outcome has prompted the charity to extend its collaboration with Stitch to two further studies set to go live in Spring 2024. In addition to these studies, Cancer Research UK will also be expanding the scope of the pilot study to provide more trial participants with the enhanced support offered by the Stitch platform.


CEO of Stitch, Jonathan Moshinsky, expressed his enthusiasm, saying:


“The input from this collaboration shaped our initial product build, so we’re delighted to see our platform providing real and tangible value to both trial participants and trial sponsors. I feel fortunate to be working with Cancer Research UK, a partner who truly understands what it means to be patient-centric, and I am excited to continue our collaboration to ensure that Stitch further reduces the participant burden of being on a clinical trial, and drive quantifiable value for sponsors.”

The feedback collected through Stitch’s platform will play a pivotal role in optimising current and future Cancer Research UK studies. By leveraging patient insights, Cancer Research UK aims to deliver trials that are not only more patient-friendly but also more effective in exploring innovative treatment options.